We Now Have TWO Antivirals To Battle CoVid

Vids https://www.instagram.com/p/DcWoqwXsnDI/The the fall and winter ahead, CoVid will be on the rise. With that in mind, know that there is a new COVID antiviral available to Americans. It is unique in that it can prevent a CoVid infection following a definite exposure to the virusXocova, or ensitrelvir, was FDA-approved in May 2026 specifically for post-exposure prevention of symptomatic COVID-19 in adults and children 12 and over. In its Phase 3 trial, 2.9% of people receiving Xocova developed COVID, compared with 9% receiving placebo, 68% reduction.The other antiviral, the familiar Paxlovid remains FDA-approved for treating mild-to-moderate COVID-19 in adults at high risk for severe disease. It should be started as soon as possible and within five days of symptom onset. Paxlovid has demonstrated a substantial reduction in hospitalizations and death for high-risk patients.Know too that both of these drugs target the coronavirus protease, and both drugs have important drug-interaction warnings.So the distinction is simple: exposed but not sick, Xocova would be the relevant option. Tested positive with symptomatic COVID and at high risk, Paxlovid remains the established oral treatment.References on my website. #COVID19 #Xocova #Ensitrelvir #Paxlovid #Antiviral